Pacific Edge says it’s on track after posting loss

Pacific Edge, which makes and markets bladder cancer tests, said its first half loss was unchanged from the year earlier period as increased revenues were channelled into development and marketing of its products, in line with its plans. The shares jumped to a seven-week high.

The Dunedin-based company posted a net loss of $4.73 million in the six months ended Sept. 30, little changed from the loss of $4.76 million in the year earlier period, it said in a statement.

Read more